A Phase 4 interventional study of Gonal-f and Recombinant human chorionic gonadotrophin (r-hCG) in Infertility, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in France. Open to female participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2018-03-30.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 15th largest by enrollment, is one of 2 that started in 2004, is one of 13 in phase 4, and was the 1st registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
Nanjing University · Sites in China
Ages 35–40 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 34 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 15th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2004, is one of 9 in phase 4, and was the 2nd registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
Clinical validation of the assisted reproductive technology (ART) treatment guidelines, which determine the optimal dose of recombinant human follicle stimulating hormone (r-hFSH) based on subject baseline characteristics/predictors of ovarian response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Also known as: follitropin alfa, Recombinant Human Follicle Stimulating Hormone (r-hFSH)
When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
Number of Oocytes Retrieved
Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: Ovum pick up day (34 to 38 hours post r-hCG administration)
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)
As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: up to end of stimulation cycle (approximately 31 days)
Mean Number of Ovarian Stimulation Days
The mean number of stimulation days were determined based on the treatment administration information collected in the case report form. Ovarian stimulation included time from first r-hFSH injection (stimulation Day) until day on which r-hCG was administered (r-hCG day). As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: up to end of stimulation cycle (approximately 31 days)
Percentage of Cycles Cancelled Due to Excessive or Inadequate Response to r-hFSH
As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: up to end of stimulation cycle (approximately 31 days)
Number of Subjects Needing Dose Adjustment
Number of subjects needing increase in dose, decrease in dose or increase and decrease both in dose were reported. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: 6 days post r-hFSH treatment
Mean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose
As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: up to end of stimulation cycle (approximately 31 days)
Embryo Implantation Rate
Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: 35-42 days post r-hCG administration
Overall Pregnancy Rate, Clinical Rate and Multiple Pregnancy Rate
Overall pregnancy rate was defined as the percentage of subjects with serum beta-hCG levels greater than 10 IU/L. Clinical pregnancy rate was defined as the percentage of subjects with at least 1 ultrasound confirmed gestational sac, with or without foetal heart activity. Multiple pregnancy rate was defined as the percentage of subjects with more than 1 ultrasound confirmed gestational sac in the uterus with fetal heart activity. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
Time frame: 35-42 days post r-hCG administration
| Milestone | Gonal-f 37.5 IU | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU | Gonal-f 262.5 IU | Gonal-f 300 IU |
|---|---|---|---|---|---|---|---|---|
| Started | 1 | 48 | 45 | 34 | 24 | 10 | 2 | 2 |
| Completed | 0 | 29 | 31 | 26 | 19 | 8 | 1 | 2 |
| Not completed | 1 | 19 | 14 | 8 | 5 | 2 | 1 | 0 |
| Withdrew: Ovarian stimulation failed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failure of down-regulation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 19 | 14 | 8 | 5 | 2 | 0 | 0 |
Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| Oocytes | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Number of Oocytes Retrieved | 8.3 ± 4.5 | 9.6 ± 6.5 | 12.1 ± 6.4 | 12.7 ± 4.3 | 8.3 ± 3.8 |
As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| International Units (IU) | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH) | 1102.3 ± 671.8 | 1287.2 ± 447.0 | 1632.4 ± 341.5 | 2043.8 ± 276.2 | 2572.5 ± 552.3 |
The mean number of stimulation days were determined based on the treatment administration information collected in the case report form. Ovarian stimulation included time from first r-hFSH injection (stimulation Day) until day on which r-hCG was administered (r-hCG day). As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| Days | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Mean Number of Ovarian Stimulation Days | 12.5 ± 4.4 | 11.0 ± 2.9 | 10.6 ± 1.8 | 11.0 ± 1.4 | 11.5 ± 2.4 |
As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| Percentage of cycles | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Excessive response | 0.0 | 0.0 | 2.9 | 0.0 | 0.0 |
| Inadequate response | 25.0 | 8.9 | 8.8 | 8.3 | 20.0 |
Number of subjects needing increase in dose, decrease in dose or increase and decrease both in dose were reported. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| subjects | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Increase | 7 | 3 | 3 | 1 | 0 |
| Decrease | 0 | 0 | 1 | 2 | 1 |
| Increase and decrease both | 2 | 3 | 0 | 0 | 0 |
As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| IU/day | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Mean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose | 84.4 ± 21.6 | 114.7 ± 16.4 | 153.6 ± 12.8 | 186.5 ± 5.8 | 223.3 ± 5.3 |
Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| Percent sacs per embryo | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Embryo Implantation Rate | 36.5 ± 42.8 | 24.3 ± 35.0 | 28.2 ± 38.9 | 37.1 ± 40.5 | 11.9 ± 20.9 |
Overall pregnancy rate was defined as the percentage of subjects with serum beta-hCG levels greater than 10 IU/L. Clinical pregnancy rate was defined as the percentage of subjects with at least 1 ultrasound confirmed gestational sac, with or without foetal heart activity. Multiple pregnancy rate was defined as the percentage of subjects with more than 1 ultrasound confirmed gestational sac in the uterus with fetal heart activity. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.
| Percentage of subjects | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Total pregnancy | 17 | 18 | 16 | 16 | 2 |
| Clinical pregnancy | 15 | 14 | 12 | 12 | 2 |
| Multiple pregnancy | 3 | 2 | 4 | 3 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gonal-f 75 IU | — | 3/48 (6.3%) | 11/48 (22.9%) |
| Gonal-f 112.5 IU | — | 3/45 (6.7%) | 15/45 (33.3%) |
| Gonal-f 150 IU | — | 1/34 (2.9%) | 5/34 (14.7%) |
| Gonal-f 187.5 IU | — | 1/24 (4.2%) | 10/24 (41.7%) |
| Gonal-f 225 IU | — | 0/10 (0%) | 3/10 (30%) |
| Event | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 2/48 | 0/45 | 0/34 | 1/24 | 0/10 |
| Ovarian torsionReproductive system and breast disorders | 0/48 | 0/45 | 1/34 | 0/24 | 0/10 |
| Pelvic painReproductive system and breast disorders | 0/48 | 1/45 | 0/34 | 0/24 | 0/10 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/48 | 1/45 | 0/34 | 0/24 | 0/10 |
| Urinary tract infectionInfections and infestations | 0/48 | 1/45 | 0/34 | 0/24 | 0/10 |
| AbortionPregnancy, puerperium and perinatal conditions | 1/48 | 0/45 | 0/34 | 0/24 | 0/10 |
| Imminent abortionPregnancy, puerperium and perinatal conditions | 1/48 | 0/45 | 0/34 | 0/24 | 0/10 |
| Jugular vein thrombosisVascular disorders | 1/48 | 0/45 | 0/34 | 0/24 | 0/10 |
| Event | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/48 | 7/45 | 0/34 | 5/24 | 1/10 |
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 1/48 | 2/45 | 1/34 | 3/24 | 1/10 |
| Breast painReproductive system and breast disorders | 0/48 | 0/45 | 0/34 | 0/24 | 1/10 |
| Myasthenic syndromeNervous system disorders | 0/48 | 0/45 | 0/34 | 0/24 | 1/10 |
| InfluenzaInfections and infestations | 1/48 | 0/45 | 0/34 | 0/24 | 1/10 |
| PneumoniaInfections and infestations | 0/48 | 0/45 | 0/34 | 0/24 | 1/10 |
| Abdominal painGastrointestinal disorders | 0/48 | 0/45 | 0/34 | 0/24 | 1/10 |
| Pelvic painReproductive system and breast disorders | 0/48 | 1/45 | 0/34 | 1/24 | 1/10 |
| Vaginal haemorrhageReproductive system and breast disorders | 3/48 | 0/45 | 0/34 | 0/24 | 0/10 |
| Abdominal pain upperGastrointestinal disorders | 0/48 | 0/45 | 2/34 | 0/24 | 0/10 |
| Age, Categorical(Participants) | Gonal-f 37.5 IU | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU | Gonal-f 262.5 IU | Gonal-f 300 IU | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 48 | 45 | 34 | 24 | 10 | 2 | 2 | 166 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Gonal-f 37.5 IU | Gonal-f 75 IU | Gonal-f 112.5 IU | Gonal-f 150 IU | Gonal-f 187.5 IU | Gonal-f 225 IU | Gonal-f 262.5 IU | Gonal-f 300 IU | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 48 | 45 | 34 | 24 | 10 | 2 | 2 | 166 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Sep 2004 to primary completion in Jan 2006, 15 months.
Results were first posted in Mar 2018, 12 years 2 months after primary completion.
Of 81 phase 4 interventional studies under Infertility, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Merck KGaA, Darmstadt, Germany →